A injection pen from Zepbound, Eli Lilly's weight loss medication, will be exhibited on December 11, 2023 in New York City.
Brendan McDermid | Reuters
Eli Lilly On Tuesday, higher doses of his weight loss medication released Zepund in single dose vials with half of the usual monthly list price to achieve more patients without insurance protection for blockbuster injection, such as: B. Patients with Medicare.
It extends the company's efforts to increase the US offer to Zepbound with increasing demand and ensure that justified patients are safe to access the actual treatment instead of cheaper versions.
Eli Lilly now offers higher doses from Zepbound in single-dose vials through a section “Self-Pay-Apotheke” on its direct-to-consumer website Lillydirect, which offered lower doses of the medicine in vials in August. Justified patients who have been used by a health service provider alone or together with an obstructive sleep apnea-zepnoe-zepbounds can pay for these vials themselves on the premises.
The company sells 7.5 milligrams and 10 milligram vials from Zepbound for $ 499 per month if patients fill their first recipe and at any time if they refill within 45 days of their previous delivery. Otherwise, these two doses cost $ 599 or 699 US dollars.
Also on Tuesday, Eli Lilly said that it reduces the price for both low-dosed vials from Zepbound by $ 50. The 2.5 milligram -vial now costs 349 US dollars, and the 5 milligrams now costs 499 US dollars, according to a publication.
Patients have to use a syringe and a needle to create the medication from a single dose of bottles and inject themselves. This differs from the dose of autoinjector pencils, the currently available form of all zepbound doses that can inject patients directly by clicking a button under their skin.
Eli Lilly said that these bottles will make more of the medication available, as they are more easily manufactured than autoinjector pencils that cost around $ 1,000 per month before insurance.
The patients usually start with a treatment with a dose of 2.5 milligrams for four weeks, then gradually increase the amount per week and later take so -called maintenance doses to keep the weight. Eli Lilly currently does not offer the highest doses of Zepbound-12.5 milligrams and 15 milligram-in single dose of single dose.
The lower pricing points for each of the single -sosing pretenders will benefit patients who are willing to pay for Zepbound themselves, and recorded in Medicare or Health plans sponsored by employers who do not cover obesity treatments.
“In the absence of a complete coverage for people who suffer from obesity, as with other chronic diseases, we are just trying to fill this space and offer a cheaper solution, especially for Medicare population,” said Patrik Jonsson, President by Eli Lilly Diabetes and Obesity, in an interview.
Medicare beneficiaries are also out of the question that Eli Lilly's savings card programs for Zepbound. Jonsson said “In an ideal world”, the Trump administration will issue a proposed rule of the biden administration to cover Medicare coverage of obesity medication. Secretary of the US Health Ministry, Robert F. Kennedy Jr., was skeptical about medication for weight loss.
Some people turned to the composite pharmacies, which even make cheaper copies of Zepbound because the brand treatment was too expensive and lack in the past few months. The US Food and Drug Administration has now declared the lack of Zepbound, which will soon prevent many compound pharmacies from making these versions of the drug.
Jonsson said that Eli Lilly was “not competing with the converters” and added that the company did not believe that “there is still a market for the mass connection”.
He said the announcement on Tuesday helps ensure that patients are “not dependent on blows that are not approved by the FDA out of security, effectiveness and quality”.
Progress of the Zepbound -bottle start
Eli Lilly refused to say how many patients previously ordered Lillydirect bottles, but Jonsson said: “The recording was really good.”
He said that Zepbound recipes, which are filled in the self-paid pharmacy of Lillydirect, which offers the individual dose of vials, will probably make up a percentage percentage with low to medium use of the broader market for obesity.
Around 10% of the new patients on the obesity market that begin treatment use Zepbound in the self -payment of Lillydirect, added Jonsson. He said that the introduction of vials of the 7.5 milligrams and 10 milligram doses would increase this number.
Lillydirect, which was introduced in January 2024, connects people with an independent telemedicine company that can prescribe certain medication if the patients are justified. The website also offers an option for household delivery when the prescribed treatment is Eli Lilly and types an online pharmacy from third-party providers to fill recipes and send them directly to patients.
In December, Direct-to Consumer Health Care Startup Ro Ro said that his platform will also offer a dosed vial from Zepbound through a new partnership with Eli Lilly.
Comments are closed.